source
- Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvalsThe FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for…BioSpace · 10d ago↗ source
- Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independenceAfter the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape wi…BioSpace · 10d ago↗ source
- How Kyverna rode CAR T’s autoimmune wave to the FDA’s doorPoised to become the first company to achieve a regulatory filing for a cell therapy in autoimmune disease, Kyverna Therapeutics is building a pipeline-in-a-product to change the treatment paradigm.